Citation & Authors
Theranostics. 2026;16(9):4865-4882.
ABSTRACT · CHINESE TRANSLATION
Translated abstract
Translated from the licensed abstract via the Chinese version. This is not an official journal translation.
Summary
Acquired drug resistance continues to undermine the clinical effectiveness of targeted cancer therapies. Although secondary genetic mutations have been extensively studied, increasing evidence identifies nongenetic metabolic reprogramming as a major driver of early cellular survival during treatment. This review develops the concept of “metabolic shapeshifters,” particularly drug-tolerant persister (DTP) cells that dynamically adjust their bioenergetic machinery to evade therapeutic stress. It examines plasticity between the conventional and reverse Warburg effects, describing how DTPs shift from glucose-dependent proliferation to a quiescent phenotype highly dependent on mitochondrial oxidative phosphorylation and fatty acid oxidation. More importantly, the perspective has expanded from intracellular reprogramming to intercellular “organelle parasitism.” Recent advances show that DTPs can actively hijack functional mitochondria from infiltrating immune cells and stromal networks through tunneling nanotubes. This predatory behavior not only restores tumor respiratory capacity but also metabolically exhausts T cells, promoting immune evasion. Finally, the review proposes strategies to dismantle this metabolic fortress: targeting vulnerabilities arising from mitochondrial dependence, disrupting the physical structures involved in organelle hijacking, and restoring immune metabolism. This multipronged framework aims to eliminate DTPs and prevent clinical relapse.
Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.
Original work license:CC BY ↗;Translations are subject to the same licensing conditions.
